Mural Oncology (MURA) Projected to Post Quarterly Earnings on Tuesday

Mural Oncology (NASDAQ:MURA) is expected to be posting its quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect Mural Oncology to post earnings of ($1.68) per share for the quarter.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same quarter in the previous year, the business posted ($3.57) EPS. On average, analysts expect Mural Oncology to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Mural Oncology Stock Up 1.5%

MURA opened at $2.63 on Monday. Mural Oncology has a 52-week low of $0.95 and a 52-week high of $4.74. The firm’s 50-day moving average price is $2.46 and its 200-day moving average price is $3.27. The company has a market cap of $45.41 million, a P/E ratio of -0.29 and a beta of 3.91.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MURA. HC Wainwright cut their price target on shares of Mural Oncology from $18.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, March 26th. Morgan Stanley downgraded shares of Mural Oncology from an “overweight” rating to an “equal weight” rating in a report on Tuesday, March 25th. Jones Trading reiterated a “hold” rating on shares of Mural Oncology in a report on Tuesday, March 25th. Finally, Raymond James downgraded shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price target on the stock. in a report on Tuesday, March 25th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.